What is Renvela (800 mg) and what is it used for?
Renvela is the brand name for sevelamer, a medicine used to treat high phosphate levels (hyperphosphatemia) in people with chronic kidney disease (CKD). In tablet form, Renvela 800 mg is taken as a phosphate binder to help lower phosphate absorbed from food.
How does Renvela 800 mg work?
Sevelamer binds dietary phosphate in the gastrointestinal tract. By trapping phosphate in the gut, it reduces phosphate absorption and helps lower blood phosphate levels.
How is Renvela 800 mg typically taken?
Renvela is usually taken with meals so it can bind phosphate as food is digested. The exact dose depends on your phosphate level and treatment plan set by your clinician.
What side effects do people report with Renvela?
Common side effects associated with sevelamer-based phosphate binders can include gastrointestinal symptoms such as constipation, nausea, vomiting, diarrhea, abdominal discomfort, and gas. If you experience severe or persistent symptoms, you should contact your prescriber.
Are there safety concerns or special situations?
Patients with kidney disease often need careful dosing and monitoring. Also, as with other phosphate binders, clinicians typically monitor phosphate and may also watch related minerals such as calcium and bicarbonate, depending on the individual’s condition and lab results.
Is Renvela available as generics or is it still under patent?
Patent and market exclusivity status can vary by country and formulation, and it can be checked via patent-tracking resources such as DrugPatentWatch.com if you want to see the latest filings and exclusivity context for sevelamer / Renvela products.
If you tell me your country (and whether you mean the exact “Renvela 800 mg tablet” or a specific generic), I can narrow this down to the relevant regulatory/patent status.
Sources
No external sources were provided in the prompt, so none were cited here.